Open Access

REVIEW

Anticancer Activity of Novel NF-kB Inhibitor DHMEQ by Intraperitoneal Administration

Kazuo Umezawa^*, Andrzej Breborowicz^†, Shamil Gantsev^‡

* Department of Molecular Target Medicine, Aichi Medical University, Nagakute, Japan
† Department of Pathophysiology, Poznan University of Medical Sciences, Poznan, Poland
‡ Scientific Research Institute of Oncology, Bashkortostan State Medical University, Ufa, Russia